Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

925
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
925
Data: Types and Distribution01:19

Data: Types and Distribution

1.3K
In biostatistics, data are the observations collected for analysis. There are two main types: parametric and non-parametric. Parametric data, which include continuous (e.g., weight) and discrete numerical data (e.g., number of tablets), assume a particular distribution pattern, often the normal distribution. Non-parametric data do not adhere to a specific distribution and typically comprise nominal (e.g., gender) and ordinal categorical data (e.g., pain scale ratings).
Distributions in...
1.3K
Regression Toward the Mean01:52

Regression Toward the Mean

6.8K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.8K
Binomial Probability Distribution01:15

Binomial Probability Distribution

15.0K
A binomial distribution is a probability distribution for a procedure with a fixed number of trials, where each trial can have only two outcomes.
The outcomes of a binomial experiment fit a binomial probability distribution. A statistical experiment can be classified as a binomial experiment if the following conditions are met:
There are a fixed number of trials. Think of trials as repetitions of an experiment. The letter n denotes the number of trials.
There are only two possible outcomes,...
15.0K
z Scores and Area Under the Curve01:17

z Scores and Area Under the Curve

17.8K
z scores are the standardized values obtained after converting a normal distribution into a standard normal distribution. A z score is measured in units of the standard deviation. The z score tells you how many standard deviations the value x is above (to the right of) or below (to the left of) the mean, μ. Values of x that are larger than the mean have positive z scores, and values of x that are smaller than the mean have negative z scores. If x equals the mean, then x has a z score of...
17.8K
Probability Distributions01:32

Probability Distributions

11.5K
 The probability of a random variable x  is the likelihood of its occurrence. A probability distribution represents the probabilities of a random variable using a formula, graph, or table. There are two types of probability distribution– discrete probability distribution and continuous probability distribution.
A discrete probability distribution is a probability distribution of discrete random variables. It can be categorized into binomial probability distribution and Poisson...
11.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of allogeneic umbilical cord blood mononuclear cells therapy in children with autism spectrum disorder and immune dysregulation: a single-center, double-blinded, randomized, placebo-controlled trial.

Stem cell research & therapy·2026
Same author

Quality and consistency of genetic newborn screening reports in China: insights from a multi-laboratory analysis using simulated samples.

BMC pediatrics·2026
Same author

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Reliable LC-MS/MS method development and validation for the determination of methylmalonic acid, methylcitric acid, malonic acid, ethylmalonic acid, and total homocysteine in dried blood spots.

Clinical biochemistry·2025
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K

Applying Beta Distribution in Analyzing Bounded Outcome Score Data.

Chuanpu Hu1, Honghui Zhou2, Amarnath Sharma2

  • 1Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania, 19477, USA. CHu25@its.jnj.com.

The AAPS Journal
|March 19, 2020
PubMed
Summary
This summary is machine-generated.

A new beta distribution method accurately analyzes bounded outcome scores (BOS) in psoriatic patients, outperforming standard methods in predicting treatment response and clinical endpoints.

Keywords:
NONMEMchange from baselinediscrete datalatent variablepopulation pharmacokinetic/pharmacodynamic modeling

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Related Experiment Videos

Last Updated: Dec 26, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Area of Science:

  • Biostatistics
  • Clinical Pharmacology
  • Longitudinal Data Analysis

Background:

  • Disease status is frequently measured using bounded outcome scores (BOS), which have discrete values and non-standard distributions (e.g., J- or U-shaped).
  • Standard statistical methods often fail with BOS data due to assumptions of normality and limited ability to simultaneously predict BOS within its range and accommodate skewness.
  • Predicting clinical response using derived disease endpoints (improvement from baseline) is a key objective not adequately addressed by existing BOS analysis methods.

Purpose of the Study:

  • To compare a novel beta distribution-based approach with standard continuous analysis for BOS data.
  • To evaluate the methods' ability to predict BOS within its natural range and accommodate non-standard distributions.
  • To assess the prediction of derived clinical endpoints and treatment response time courses.

Main Methods:

  • Utilized a mechanism-based longitudinal exposure-response model.
  • Analyzed data from two Phase 3 clinical studies involving psoriatic patients.
  • Compared the performance of the beta distribution-based approach against the standard continuous analysis approach.

Main Results:

  • The beta distribution-based approach demonstrated superior performance in describing BOS data compared to standard methods.
  • This novel approach proved more effective in predicting derived clinical endpoints.
  • The beta distribution method also accurately predicted the response time course in a sensitive subpopulation.

Conclusions:

  • The beta distribution-based approach offers a superior and more comprehensive method for analyzing BOS data in clinical studies.
  • This method effectively addresses the challenges of non-standard distributions and prediction of clinical response endpoints.
  • The findings support the adoption of the beta distribution approach for improved BOS data analysis and clinical trial outcomes prediction.